{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:34:40Z","timestamp":1790670880046,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,24]],"date-time":"2015-07-24T00:00:00Z","timestamp":1437696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014389","name":"Amarin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.atherosclerosis.2015.07.035","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T06:18:16Z","timestamp":1437545896000},"page":"357-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":167,"title":["Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis"],"prefix":"10.1016","volume":"242","author":[{"given":"Kenneth M.","family":"Borow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Preston","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.atherosclerosis.2015.07.035_bib1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.282.8.790","article-title":"Are surrogate markers adequate to assess cardiovascular disease drugs?","volume":"282","author":"Temple","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.07.035_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/jech.2004.027524","article-title":"A\u00a0philosophical analysis of the Hill criteria","volume":"59","author":"Thygesen","year":"2005","journal-title":"J.\u00a0Epidemiol. Community Health"},{"issue":"9943","key":"10.1016\/j.atherosclerosis.2015.07.035_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2015.07.035_bib4","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.07.035_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc Diabetol."},{"issue":"9567","key":"10.1016\/j.atherosclerosis.2015.07.035_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2015.07.035_bib8","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of Cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2015.07.035_bib9","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.07.035_bib10","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/ATVBAHA.114.305012","article-title":"Ezetimibe: rescued by randomization (clinical and Mendelian)","volume":"35","author":"McPherson","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2015.07.035_bib11","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2015.07.035_bib12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2015.07.035_bib13","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMe1507041","article-title":"Proof that lower is better - LDL cholesterol and IMPROVE-IT","volume":"372","author":"Jarcho","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2015.07.035_bib14","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1194\/jlr.R027904","article-title":"Omega-3 fatty acid supplementation and cardiovascular disease","volume":"53","author":"Jump","year":"2012","journal-title":"J.\u00a0Lipid Res."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.07.035_bib15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/ajcn\/79.6.935","article-title":"Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms","volume":"79","author":"Larsson","year":"2004","journal-title":"Am. J. Clin. Nutr."},{"issue":"6 Suppl.\u00a0l","key":"10.1016\/j.atherosclerosis.2015.07.035_bib16","doi-asserted-by":"crossref","first-page":"1467S","DOI":"10.1093\/ajcn\/83.6.1467S","article-title":"Distribution, interconversion, and dose response of n-3 fatty acids in humans","volume":"83","author":"Arterburn","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"Am. J. Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bbamem.2014.10.016","article-title":"Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism","volume":"1848","author":"Mason","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200\u2013500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study","volume":"12","author":"Brinton","year":"2013","journal-title":"Cardiovasc Diabetol."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2015.07.035_bib20","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jacc.2011.06.063","article-title":"Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events","volume":"58","author":"Mozaffarian","year":"2011","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2015.07.035_bib21","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2013.08.1626","article-title":"How do statins work?: changing paradigms with implications for statin allocation","volume":"62","author":"Blaha","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1742-7843.2011.00785.x","article-title":"Reactive oxygen species and endothelial function\u2013role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases","volume":"110","author":"Montezano","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.07.035_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","article-title":"Atherosclerosis. the road ahead","volume":"104","author":"Glass","year":"2001","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"TG and HDL Working Group of the Exome Sequencing Project NHLaBI","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib26","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/ATVBAHA.114.305172","article-title":"Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics","volume":"35","author":"Khetarpal","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2015.07.035_bib27","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","article-title":"Triglycerides on the rise: should we swap seats on the seesaw?","volume":"36","author":"Libby","year":"2015","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2015.07.035_bib28","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1161\/01.CIR.99.22.2858","article-title":"Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease","volume":"99","author":"Kugiyama","year":"1999","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2015.07.035_bib29","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jacc.2003.09.074","article-title":"Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus","volume":"43","author":"Fukushima","year":"2004","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.07.035_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1194\/jlr.M700505-JLR200","article-title":"Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation","volume":"50","author":"Wang","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.07.035_bib32","doi-asserted-by":"crossref","first-page":"H2745","DOI":"10.1152\/ajpheart.00686.2006","article-title":"Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis","volume":"292","author":"Eiselein","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5551\/jat1994.1.98","article-title":"Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages","volume":"1","author":"Tomono","year":"1994","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2015.07.035_bib34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.ATV.14.11.1767","article-title":"Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque","volume":"14","author":"Rapp","year":"1994","journal-title":"Arterioscler. Thromb."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.07.035_bib35","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.CIR.102.6.670","article-title":"Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism","volume":"102","author":"Doi","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2015.07.035_bib36","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1161\/01.ATV.20.7.1835","article-title":"Plasma lipoproteins enhance tissue factor-independent factor VII activation","volume":"20","author":"Kjalke","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.07.035_bib37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/01.ATV.18.3.458","article-title":"Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes","volume":"18","author":"Moyer","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2015.07.035_bib38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/01.ATV.16.5.697","article-title":"Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression","volume":"16","author":"Mack","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8550","key":"10.1016\/j.atherosclerosis.2015.07.035_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(87)92734-6","article-title":"Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men","volume":"2","author":"Krauss","year":"1987","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157016112798829760","article-title":"The role of nitric oxide on endothelial function","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.07.035_bib41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2014.02.074","article-title":"Combination eicosapentaenoic acid and statin treatment reversed endothelial dysfunction in HUVECs exposed to oxidized LDL","volume":"8","author":"Mason","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.07.035_bib42","doi-asserted-by":"crossref","first-page":"10334","DOI":"10.3390\/ijms150610334","article-title":"Eicosapentaenoic acid protects against palmitic acid-induced endothelial dysfunction via activation of the AMPK\/eNOS pathway","volume":"15","author":"Lee","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib43","doi-asserted-by":"crossref","DOI":"10.5551\/jat.28167","article-title":"Eicosapentaenoic acid prevents saturated fatty acid-induced vascular endothelial dysfunction: involvement of long-chain acyl-CoA synthetase","author":"Ishida","year":"2015","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.07.035_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacl.2011.03.011","article-title":"Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors","volume":"5","author":"Mason","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2015.07.035_bib45","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jnutbio.2014.04.007","article-title":"Eicosapentaenoic acid induces neovasculogenesis in human endothelial progenitor cells by modulating c-kit protein and PI3-K\/Akt\/eNOS signaling pathways","volume":"25","author":"Chiu","year":"2014","journal-title":"J.\u00a0Nutr. Biochem."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.07.035_bib46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1507\/endocrj.EJ11-0394","article-title":"Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function","volume":"59","author":"Sasaki","year":"2012","journal-title":"Endocr. J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10557-013-6496-3","article-title":"Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease","volume":"28","author":"Toyama","year":"2014","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib48","doi-asserted-by":"crossref","first-page":"754181","DOI":"10.1155\/2012\/754181","article-title":"Eicosapentaenoic acid supplementation changes fatty acid composition and corrects endothelial dysfunction in hyperlipidemic patients","volume":"2012","author":"Yamakawa","year":"2012","journal-title":"Cardiol. Res. Pract."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2015.07.035_bib49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.5551\/jat.7260","article-title":"Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study","volume":"18","author":"Takaki","year":"2011","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2015.07.035_bib50","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1194\/jlr.R700001-JLR200","article-title":"Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase","volume":"48","author":"Zheng","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.atherosclerosis.2015.07.035_bib51","first-page":"A16803","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies","volume":"130","author":"Ballantyne","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2337\/dc06-1179","article-title":"Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome","volume":"30","author":"Satoh","year":"2007","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2015.07.035_bib53","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/ATVBAHA.110.221127","article-title":"Monocyte and macrophage dynamics during atherogenesis","volume":"31","author":"Ley","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2015.07.035_bib54","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2013.07.043","article-title":"Monocytes in coronary artery disease and atherosclerosis: where are we now?","volume":"62","author":"Ghattas","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5551\/jat.E091","article-title":"Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes","volume":"16","author":"Nomura","year":"2009","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib56","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.jss.2012.04.010","article-title":"Effects of fatty acids on endothelial cells: inflammation and monocyte adhesion","volume":"177","author":"Grenon","year":"2012","journal-title":"J.\u00a0Surg. Res."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2015.07.035_bib57","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1161\/ATVBAHA.108.171736","article-title":"In\u00a0vivo and in\u00a0vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid","volume":"28","author":"Yamada","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9356","key":"10.1016\/j.atherosclerosis.2015.07.035_bib58","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(03)12468-3","article-title":"Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial","volume":"361","author":"Thies","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib59","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","article-title":"Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma","volume":"234","author":"Nishio","year":"2014","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.07.035_bib60","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-011-0210-3","article-title":"Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis","volume":"13","author":"Wei","year":"2011","journal-title":"Curr. Atheroscler. Rep."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2015.07.035_bib61","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2015.07.035_bib62","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/eurheartj\/ehp477","article-title":"Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies","volume":"30","author":"Klingenberg","year":"2009","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2015.07.035_bib63","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jnutbio.2009.12.004","article-title":"Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids","volume":"21","author":"Adkins","year":"2010","journal-title":"J.\u00a0Nutr. Biochem."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2013.10.006","article-title":"Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases","volume":"19","author":"Spite","year":"2014","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2015.07.035_bib65","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/ATVBAHA.115.305324","article-title":"Resolvin E1 attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis","volume":"35","author":"Hasturk","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib66","series-title":"Vascepa [package Insert]","year":"2015"},{"issue":"43","key":"10.1016\/j.atherosclerosis.2015.07.035_bib67","doi-asserted-by":"crossref","first-page":"32720","DOI":"10.1074\/jbc.M110.118406","article-title":"Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of \u03c9-3 fatty acids","volume":"285","author":"Arnold","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.07.035_bib68","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bbalip.2014.07.020","article-title":"Cytochrome P epoxygenase pathway of polyunsaturated fatty acid metabolism","volume":"1851","author":"Spector","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"5431","key":"10.1016\/j.atherosclerosis.2015.07.035_bib69","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","article-title":"Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids","volume":"285","author":"Node","year":"1999","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.07.035_bib70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/met.2014.0137","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity C-reactive protein and lipid parameters in patients with metabolic syndrome","volume":"13","author":"Bays","year":"2015","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib71","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijcard.2014.08.055","article-title":"Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study","volume":"176","author":"Doi","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib72","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.atherosclerosis.2010.06.046","article-title":"Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents","volume":"212","author":"Dangardt","year":"2010","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2015.07.035_bib73","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2337\/dc12-0269","article-title":"Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia","volume":"35","author":"Satoh-Asahara","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib74","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2010.05.022","article-title":"Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability","volume":"212","author":"Cawood","year":"2010","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.amjcard.2012.08.038","article-title":"Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease","volume":"111","author":"Nozue","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jjcc.2013.06.016","article-title":"Ratio of eicosapentaenoic acid to arachidonic acid is a critical risk factor for acute coronary syndrome in middle-aged older patients as well as younger adult patients","volume":"63","author":"Serikawa","year":"2014","journal-title":"J.\u00a0Cardiol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2015.07.035_bib77","first-page":"610","article-title":"Eicosapentaenoic acid to arachidonic acid ratio is associated with the presence of thin-cap fibroatheroma determined by optical coherence tomography","volume":"35","author":"Wakabayashi","year":"2014","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.07.035_bib78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.plefa.2013.07.005","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)","volume":"89","author":"Braeckman","year":"2013","journal-title":"Prostagl. Leukot. Essent. Fat. Acids"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2015.07.035_bib79","first-page":"137","article-title":"Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with optimal LDL cholesterol lowering therapy","volume":"34","author":"Domei","year":"2013","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.atherosclerosis.2014.10.011","article-title":"Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia","volume":"237","author":"Tanaka","year":"2014","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib81","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5551\/jat.25593","article-title":"Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study","volume":"22","author":"Yamano","year":"2015","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2015.07.035_bib82","first-page":"1011","article-title":"The additional effect of eicosapentanoic acid on coronary plaque stability in stable angina patients with statin use by optical coherence tomography analysis","volume":"34","author":"Uehara","year":"2013","journal-title":"Eur. Heart J."},{"issue":"21Suppl.\u00a0l","key":"10.1016\/j.atherosclerosis.2015.07.035_bib83","first-page":"14434","article-title":"Effects of additional eicosapentaenoic acid to statin therapy on inflammatory cytokines and the tissue characterization of coronary plaque assessed by integrated backscatter intravascular ultrasound systems","volume":"126","author":"Niki","year":"2012","journal-title":"Circulation"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2015.07.035_bib84","article-title":"High-purity-eicosapentaenoic-acid in addition to a strong statin makes regression of coronary plaque in patients with angina-pectoris and impaired glucose tolerance","volume":"77","author":"Wakita","year":"2013","journal-title":"Circ. J."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2015.07.035_bib85","doi-asserted-by":"crossref","first-page":"E1731","DOI":"10.1016\/S0735-1097(12)61732-X","article-title":"The impact of a pure-EPA omega-3 fatty acid on coronary plaque stabilization: a plaque component analysis with 64-slice multi-detector row computed tomography","volume":"59","author":"Shintani","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib86","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.atherosclerosis.2006.03.005","article-title":"Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes","volume":"191","author":"Mita","year":"2007","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2015.07.035_bib87","first-page":"863","article-title":"Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia","volume":"32","author":"Katoh","year":"2011","journal-title":"Ther. Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib88","first-page":"177","article-title":"Effect of highly purified eicosapentaenoic acid (EPA) for patients with multiple artery atherosclerotic risk factors and clinical usefulness of the ratio of serum EPA to arachidonic acid (AA) as the indicator of therapy effect of atherosclerosis","volume":"35","author":"Maeda","year":"2014","journal-title":"Ther. Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib89","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.76.2.944","article-title":"Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties","volume":"76","author":"Needleman","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2015.07.035_bib90","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2015.07.035_bib91","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.07.035_bib92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacl.2014.02.036","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies","volume":"8","author":"Ballantyne","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.07.035_bib93","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev. Cardiovasc Ther."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.07.035_bib94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2015.07.035_bib95","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1253\/circj.CJ-08-1197","article-title":"Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease","volume":"73","author":"Matsuzaki","year":"2009","journal-title":"Circ. J."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2015.07.035_bib96","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1161\/STROKEAHA.107.509455","article-title":"Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial","volume":"39","author":"Tanaka","year":"2008","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib97","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.atherosclerosis.2009.03.029","article-title":"Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA lipid intervention study (JELIS)","volume":"206","author":"Oikawa","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib98","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.5876","article-title":"Relationships between plasma fatty acid composition and coronary artery disease","volume":"18","author":"Itakura","year":"2011","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2015.07.035_bib99","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5551\/jat.8326","article-title":"Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA lipid intervention study (JELIS)","volume":"19","author":"Sasaki","year":"2012","journal-title":"J.\u00a0Atheroscler. Thromb."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2015.07.035_bib100","first-page":"271","article-title":"Eicosapentaenoic acid restrains the development of the cardiovascular events independent of triglyceride and C-reactive protein reduction in Japanese hemodialysis patients","volume":"34","author":"Nasu","year":"2013","journal-title":"Eur. Heart J."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.atherosclerosis.2015.07.035_bib101","first-page":"i257","article-title":"Eicosapentaenoic acid (EPA) is an independent predictor of all-cause mortality in hemodialysis patients","volume":"28","author":"Inoue","year":"2013","journal-title":"Nephrol. Dial. Transpl."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.atherosclerosis.2015.07.035_bib102","first-page":"iii240","article-title":"EPA ethyl ester increases EPA\/AA ratio and decreases carboxylmethyl lysine in dialysis patients","volume":"29","author":"Inagaki","year":"2014","journal-title":"Nephrol. Dial. Transpl."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2015.07.035_bib103","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1681\/ASN.V10102177","article-title":"Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in\u00a0vivo peroxidation of LDL in dialysis patients","volume":"10","author":"Ando","year":"1999","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"issue":"9177","key":"10.1016\/j.atherosclerosis.2015.07.035_bib104","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico","volume":"354","author":"GISSI Prevenzione Investigators","year":"1999","journal-title":"Lancet"},{"issue":"9645","key":"10.1016\/j.atherosclerosis.2015.07.035_bib105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"GISSI-HF Investigators","year":"2008","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2015.07.035_bib106","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n-3 fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2015.07.035_bib107","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"ORIGIN Trial Investigators","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2015.07.035_bib108","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2015.07.035_bib109","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.2012.28733","article-title":"Fish oil and postoperative atrial fibrillation: the omega-3 fatty acids for prevention of Post-operative atrial fibrillation (OPERA) randomized trial","volume":"308","author":"Mozaffarian","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib110","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","article-title":"n-3 fatty acids in patients with multiple cardiovascular risk factors","volume":"368","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib111","series-title":"Lovaza [package Insert]","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib112","series-title":"Epanova [package Insert]","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib113","series-title":"Omtryg [package Insert]","year":"2014"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2015.07.035_bib114","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.jacc.2015.03.543","article-title":"The remnants of residual risk","volume":"65","author":"Joshi","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.07.035_bib115","doi-asserted-by":"crossref","first-page":"A243","DOI":"10.1161\/circoutcomes.8.suppl_2.243","article-title":"A\u00a0novel cost effectiveness model of eicosapentaenoic acid (EPA) for secondary prevention in the United States","volume":"8","author":"Schmier","year":"2015","journal-title":"Circ. Cardiovasc Qual. Outcomes"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015300551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015300551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T18:54:08Z","timestamp":1652900048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015300551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0021915015300551"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.07.035","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}